PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Format: Artigo
Jezik:Inglês
Izdano: Paediatrician Publishers, LLC 2012-08-01
Serija:Pediatričeskaâ Farmakologiâ
Teme:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Online pristup:https://www.pedpharma.ru/jour/article/view/302
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items